Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

A Zanichelli, M Maurer, W Aberer, T Caballero, H J Longhurst, L Bouillet, V Fabien, I Andresen, IOS Study Group, A Grumach, A Bygum, C Blanchard Delaunay, I Boccon-Gibod, B Coppere, A Du Thanh, C Dzviga, O Fain, B Goichot, A Gompel, S Guez, P Jeandel, G Kanny, D Launay, H Maillard, L Martin, A Masseau, Y Ollivier, A Sobel, E Aygören-Pürsün, M Bas, A Bauer, K Bork, J Greve, M Magerl, I Martinez Saguer, U Strassen, E Papadopoulou-Alataki, F Psarros, Y Graif, S Kivity, A Reshef, E Toubi, F Arcoleo, M Bova, M Cicardi, P Manconi, G Marone, V Montinaro, M Triggiani, L Baeza, R Cabañas, G Gala Ortiz, M Guilarte, D Hernandez, C Hernando de Larramendi, R Lleonart, T Lobera, L Marques, B Saenz de San Pedro, J Björkander, C Bethune, T Garcez, A Zanichelli, M Maurer, W Aberer, T Caballero, H J Longhurst, L Bouillet, V Fabien, I Andresen, IOS Study Group, A Grumach, A Bygum, C Blanchard Delaunay, I Boccon-Gibod, B Coppere, A Du Thanh, C Dzviga, O Fain, B Goichot, A Gompel, S Guez, P Jeandel, G Kanny, D Launay, H Maillard, L Martin, A Masseau, Y Ollivier, A Sobel, E Aygören-Pürsün, M Bas, A Bauer, K Bork, J Greve, M Magerl, I Martinez Saguer, U Strassen, E Papadopoulou-Alataki, F Psarros, Y Graif, S Kivity, A Reshef, E Toubi, F Arcoleo, M Bova, M Cicardi, P Manconi, G Marone, V Montinaro, M Triggiani, L Baeza, R Cabañas, G Gala Ortiz, M Guilarte, D Hernandez, C Hernando de Larramendi, R Lleonart, T Lobera, L Marques, B Saenz de San Pedro, J Björkander, C Bethune, T Garcez

Abstract

The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real-world setting. We analyzed safety data from 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off-label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs). The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icatibant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to icatibant. Notably, no SAEs related to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at a frequency above label guidelines. Additionally, no major differences were noted in AEs occurring in on-label vs off-label icatibant users.

Keywords: angioedema; icatibant; real-world; safety.

© 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.

References

    1. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M et al. Icatibant, a new bradykinin‐receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532–541.
    1. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D et al. Randomized placebo‐controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST‐3 trial. Ann Allergy Asthma Immunol 2011;107:529–537.
    1. Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A et al. Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial. Clin Exp Immunol 2014;177:544–553.
    1. Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A et al. Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema. Allergy 2014;69:305–314.
    1. Bas M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study. Allergy 2013;68:1452–1459.
    1. Kränkel N, Kuschnerus K, Müller M, Speer T, Mocharla P, Madeddu P et al. Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair‐promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 2013;127:594–603.
    1. Yao Y, Sheng Z, Li Y, Yan F, Fu C, Ma G et al. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther 2012;23:859–870.
    1. Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013;8:e53773.
    1. Firazyr® (icatibant) summary of product characteristics . Available at: (accessed 9 September 2016).
    1. Firazyr® (icatibant) [package insert]. Shire Orphan Therapies, LLC: Lexington, MA; 2015.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅